Proteomics for prediction and characterization of response to infliximab in Crohn's disease: a pilot study.
OBJECTIVE
Infliximab is the first anti-TNFalpha accepted by the Food and Drug Administration for use in inflammatory bowel disease treatment. Few clinical, biological and genetic factors tend to predict response in Crohn's disease (CD) patient subcategories, none widely predicting response to infliximab.


METHODS
Twenty CD patients showing clinical response or non response to infliximab were used for serum proteomic profiling on Surface Enhanced Lazer Desorption Ionisation-Time of Flight-Mass Spectrometry (SELDI-TOF-MS), each before and after treatment. Univariate and multivariate data analysis were performed for prediction and characterization of response to infliximab.


RESULTS
We obtained a model of classification predicting response to treatment and selected relevant potential biomarkers, among which platelet aggregation factor 4 (PF4). We quantified PF4, sCD40L and IL-6 by ELISA for correlation studies.


CONCLUSIONS
This first proteomic pilot study on response to infliximab in CD suggests association between platelet metabolism and response to infliximab and requires validation studies on a larger cohort of patients.
Meuwis
Marie-Alice
MA
Laboratory of Clinical Chemistry, GIGA Research, University of Liège, Belgium.
Fillet
Marianne
M
Lutteri
Laurence
L
Marée
Raphaël
R
Geurts
Pierre
P
de Seny
Dominique
D
Malaise
Michel
M
Chapelle
Jean-Paul
JP
Wehenkel
Louis
L
Belaiche
Jacques
J
Merville
Marie-Paule
MP
Louis
Edouard
E
D000328:Adult; D000704:Analysis of Variance; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D023201:CD40 Ligand / Q000097:blood; D003424:Crohn Disease / Q000097:blood / Q000188:drug therapy*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D000069285:Infliximab; D015850:Interleukin-6 / Q000097:blood; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D010865:Pilot Projects; D010978:Platelet Factor 4 / Q000097:blood; D011379:Prognosis; D040901:Proteomics; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D015415:Biomarkers; D015850:Interleukin-6; D023201:CD40 Ligand; D010978:Platelet Factor 4; D000069285:Infliximab